News
Changes in Intestinal Microflora Correlate with Disease Activity in Patients with Lupus Erythematosus
The role of intestinal microflora in the pathogenesis of autoimmune diseases, including lupus erythematosus, has been discussed for a long time. An American study discovered a specific bacterium…
Risk Factors and Therapy of Chronic Leg Ulcers Lasting More Than 6 Months
The therapy of chronic leg ulcers in diabetics continues to be a significant challenge for attending physicians and surgeons. Authors of a recently published study have addressed the risk factors, clinical...
LDL cholesterol: a new risk factor for the onset of venous thromboembolic disease?
Not only do atherosclerotic plaques in the arteries and the risk of heart attack decrease along with LDL cholesterol levels. Results from a large molecular genetic study suggest that lowering its…
Polatuzumab Vedotin in Combination Treatment of Patients with R/R DLBCL
Polatuzumab Vedotin is a conjugate of a cytostatic agent and an antibody against CD79b, a component of the B-lymphocyte receptor typically expressed by diffuse large B-cell lymphoma (DLBCL) cells. In…
End of Unnecessary Biopsies? Prostate Health Index (PHI) in Detecting Aggressive Carcinoma
The Prostate Health Index (PHI) combines the results of three blood-derived parameters: total PSA (tPSA), free PSA (fPSA), and [-2]proPSA (p2PSA) into a single numerical score: PHI = (p2PSA / fPSA ×…
Prediction of Cancer Aggressiveness: Prostate Health Index (PHI) as a Promising Future Marker
The Prostate Health Index (PHI) is a diagnostic blood test that combines the levels of prostate-specific antigen (PSA), free PSA (fPSA), and the isoform [-2]proPSA (p2PSA). Its use in prostate cancer…
Cardiovascular Benefit of SGLT2 Inhibitors Confirmed
The cardiovascular (CV) benefit of SGLT2 inhibitors in type 2 diabetics, demonstrated by empagliflozin in the EMPA-REG OUTCOME study, has also been confirmed by studies with canagliflozin (CANVAS), a...
Why Do Women in the USA Receive Indicated Statin Therapy Less and in Lower Doses Than Men?
Statin use has been proven to reduce the risk of cardiovascular diseases in both men and women. However, women in the USA who are indicated for this treatment have historically taken it less…
Efficacy and Safety of High Doses of Enoxaparin in Preventing Thromboembolic Disease in Morbidly Obese Patients
Thromboembolic disease is a significant cause of morbidity and mortality in hospitalized patients, with morbid obesity being a notable risk factor for thromboembolism. Various thromboprophylaxis…
Prophylaxis of Thromboembolism with Low-Molecular-Weight Heparins in Oncology Patients: Efficacy and Safety of Doses Adjusted According to Anti-Xa Activity
Oncological patients undergoing surgical procedures are observed to have a high risk of thromboembolic complications. Recommended prophylactic dosing of low-molecular-weight heparins (LMWH) is often…
Evaluation of the m7-FLIPI score in patients with follicular lymphoma revealed a promising predictive biomarker for determining suitable chemotherapy
The authors of a study presented at the December congress of the American Society of Hematology (ASH) in Orlando introduced a new prognostic tool, m7-FLIPI, for determining the risk level of patients…
Kadcyla in a New Indication – Adjuvant Therapy for Early HER2+ Breast Cancer
In December, the European Commission approved the expansion of the indication for Roche's medicinal product Kadcyla, which contains the active substance trastuzumab emtansine. This expansion makes…
Comparison of Safety and Efficacy of Oral and Intravenous Administration of Combination NEPA in the Prophylaxis of Chemotherapy-Induced Nausea and Vomiting
Both oral and intravenous administration of a combination of netupitant (a neurokinin 1 receptor antagonist − NK1RA) with palonosetron (a 5-HT3 receptor antagonist) offer prevention of…
Cost Effectiveness of Netupitant/Palonosetron Combination in the Prophylaxis of Chemotherapy-Induced Nausea and Vomiting
A recently published study compared the costs of achieving a complete response to antiemetic therapy in the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) when using a combination of…